BACKGROUND: The outcome is reported of a prospective uncontrolled study based on a stepwise treatment protocol during an outbreak of severe acute respiratory syndrome (SARS) in Hong Kong. METHOD: One hundred and thirty eight patients were treated with broad spectrum antibiotics, a combination of ribavirin and low dose corticosteroid, and then intravenous high dose methylprednisolone according to responses. Sustained response to treatment was defined as (1) defervescence for > or =4 consecutive days, (2) resolution of lung consolidation by >25%, and (3) oxygen independence by the fourth day without fever. Patients with defervescence who achieved either criterion 2 or 3 were classified as partial responders. Patients who fell short of criteria 2 and 3 were non-responders. RESULTS: Laboratory confirmation of SARS coronavirus infection was established in 132 (95.7%). None responded to antibiotics but 25 (18.1%) responded to ribavirin + low dose corticosteroid. Methylprednisolone was used in 107 patients, of whom 95 (88.8%) responded favourably. Evidence of haemolytic anaemia was observed in 49 (36%). A high level of C-reactive protein at presentation was the only independent predictor for use of methylprednisolone (odds ratio 2.18 per 10 mg/dl increase, 95% confidence interval 1.12 to 4.25, p = 0.02). Thirty seven patients (26.8%) required admission to the intensive care unit and 21 (15.2%) required invasive mechanical ventilation. There were 15 deaths (mortality rate 10.9%), most with significant co-morbidities, whereas 122 (88.4%) had been discharged home 4 months after the outbreak onset. CONCLUSION: The use of high dose pulse methylprednisolone during the clinical course of a SARS outbreak was associated with clinical improvement, but randomised controlled trials are needed to ascertain its efficacy in this condition.
BACKGROUND: The outcome is reported of a prospective uncontrolled study based on a stepwise treatment protocol during an outbreak of severe acute respiratory syndrome (SARS) in Hong Kong. METHOD: One hundred and thirty eight patients were treated with broad spectrum antibiotics, a combination of ribavirin and low dose corticosteroid, and then intravenous high dose methylprednisolone according to responses. Sustained response to treatment was defined as (1) defervescence for > or =4 consecutive days, (2) resolution of lung consolidation by >25%, and (3) oxygen independence by the fourth day without fever. Patients with defervescence who achieved either criterion 2 or 3 were classified as partial responders. Patients who fell short of criteria 2 and 3 were non-responders. RESULTS: Laboratory confirmation of SARS coronavirus infection was established in 132 (95.7%). None responded to antibiotics but 25 (18.1%) responded to ribavirin + low dose corticosteroid. Methylprednisolone was used in 107 patients, of whom 95 (88.8%) responded favourably. Evidence of haemolytic anaemia was observed in 49 (36%). A high level of C-reactive protein at presentation was the only independent predictor for use of methylprednisolone (odds ratio 2.18 per 10 mg/dl increase, 95% confidence interval 1.12 to 4.25, p = 0.02). Thirty seven patients (26.8%) required admission to the intensive care unit and 21 (15.2%) required invasive mechanical ventilation. There were 15 deaths (mortality rate 10.9%), most with significant co-morbidities, whereas 122 (88.4%) had been discharged home 4 months after the outbreak onset. CONCLUSION: The use of high dose pulse methylprednisolone during the clinical course of a SARS outbreak was associated with clinical improvement, but randomised controlled trials are needed to ascertain its efficacy in this condition.
Authors: L Gattinoni; G Tognoni; A Pesenti; P Taccone; D Mascheroni; V Labarta; R Malacrida; P Di Giulio; R Fumagalli; P Pelosi; L Brazzi; R Latini Journal: N Engl J Med Date: 2001-08-23 Impact factor: 91.245
Authors: C Y Cheung; L L M Poon; A S Lau; W Luk; Y L Lau; K F Shortridge; S Gordon; Y Guan; J S M Peiris Journal: Lancet Date: 2002-12-07 Impact factor: 79.321
Authors: Nelson Lee; David Hui; Alan Wu; Paul Chan; Peter Cameron; Gavin M Joynt; Anil Ahuja; Man Yee Yung; C B Leung; K F To; S F Lui; C C Szeto; Sydney Chung; Joseph J Y Sung Journal: N Engl J Med Date: 2003-04-07 Impact factor: 91.245
Authors: Kenneth W Tsang; Pak L Ho; Gaik C Ooi; Wilson K Yee; Teresa Wang; Moira Chan-Yeung; Wah K Lam; Wing H Seto; Loretta Y Yam; Thomas M Cheung; Poon C Wong; Bing Lam; Mary S Ip; Jane Chan; Kwok Y Yuen; Kar N Lai Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245
Authors: Luciana Borio; Thomas Inglesby; C J Peters; Alan L Schmaljohn; James M Hughes; Peter B Jahrling; Thomas Ksiazek; Karl M Johnson; Andrea Meyerhoff; Tara O'Toole; Michael S Ascher; John Bartlett; Joel G Breman; Edward M Eitzen; Margaret Hamburg; Jerry Hauer; D A Henderson; Richard T Johnson; Gigi Kwik; Marci Layton; Scott Lillibridge; Gary J Nabel; Michael T Osterholm; Trish M Perl; Philip Russell; Kevin Tonat Journal: JAMA Date: 2002-05-08 Impact factor: 56.272
Authors: P T Tassios; C Chadjichristodoulou; M Lambiri; A Kansouzidou-Kanakoudi; Z Sarandopoulou; J Kourea-Kremastinou; L S Tzouvelekis; N J Legakis Journal: Emerg Infect Dis Date: 2000 Jan-Feb Impact factor: 6.883
Authors: Kar Neng Lai; Joseph C K Leung; Christine N Metz; Fernand M Lai; Richard Bucala; Hui Yao Lan Journal: J Pathol Date: 2003-04 Impact factor: 7.996
Authors: Loletta K-Y So; Arthur C W Lau; Loretta Y C Yam; Thomas M T Cheung; Edwin Poon; Raymond W H Yung; K Y Yuen Journal: Lancet Date: 2003-05-10 Impact factor: 79.321
Authors: D S Hui; G M Joynt; K T Wong; C D Gomersall; T S Li; G Antonio; F W Ko; M C Chan; D P Chan; M W Tong; T H Rainer; A T Ahuja; C S Cockram; J J Y Sung Journal: Thorax Date: 2005-05 Impact factor: 9.139
Authors: A C Ghani; C A Donnelly; D R Cox; J T Griffin; C Fraser; T H Lam; L M Ho; W S Chan; R M Anderson; A J Hedley; G M Leung Journal: Am J Epidemiol Date: 2005-08-02 Impact factor: 4.897